An Ozempic Relative Slowed Parkinson's Disease in a Small Study
·1 min
In a recent study, French researchers have reported a modest slowdown in the progression of Parkinson’s disease using a GLP-1 receptor agonist, a drug commonly used to treat diabetes and obesity. This development comes after decades of unsuccessful clinical trials. Parkinson’s disease affects half a million Americans and is the second most prevalent degenerative brain illness after Alzheimer’s. Symptoms include tremors, slowness, stiffness, and balance challenges, often leading to difficulties in basic activities. Although treatments like deep brain stimulation exist, this potential breakthrough offers hope for managing the disease.